January 19, 2021
Canadian-based biopharma, Aurinia Pharmaceuticals, is awaiting FDA approval of their promising treatment for lupus nephritis. With ambitious plans to take their drug to market on their own, Aurinia has raised a considerable amount of money and grown to over 300 employees.
For more from Sean Silcoff, with comments from our head of equity research, David Martin, click here.